Replies to post #34315 on Humanigen Inc (HGENQ)

[DonDonDonDon]

Granted, the trial doctors noted a correlation of CRP levels to our results, and announced those results on patients as you mention with CRP < 150 mg/L, and < 85 years old.

Nope, I never mentioned <85yo. The 154% efficacy is for patients with a CRP<150mg/L. When <85yo is added in, efficacy climbs to 2.96-fold/196% efficacy.

Exploratory analysis of LIVE-AIR results in patients with CRP<150 mg/L and aged <85 years of age...show lenzilumab improved the likelihood of survival without ventilation by more than 3-fold (OR 3.04; 95% CI: 1.68-5.51, nominal p=0.0003) compared with placebo and mortality was improved by more than 2-fold (OR: 2.22; 95%CI: 1.07-4.67, p=0.034).

Nope, the 3.04-fold/204% efficacy on primary endpoint and 2.22-fold/122% efficacy on mortality are for patients with CRP<150mg/L + <85yo combined with remdesivir and steroids.

So patients with CRP<150mg/L had 154% efficacy on the primary endpoint. Efficacy rose to 196% efficacy for patients with CRP<150mg/L and <85yo. Efficacy rose to 204% efficacy for patients with CRP<150mg/L and <85yo and on remdesivir and steroids.

I solely showed 154% efficacy for patients with CRP<150mg/L because it is game-changing efficacy without complicating it by adding age requirements and other drugs.